An internal standard for the quantification of alvimopan
Related Products
Unlabeled Version(s)
23902Alvimopan
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Alvimopan-d5

Item No. 33812

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-(phenyl-d5)propyl]-glycine
Synonyms
  • ADL 8-2698-d5
Molecular Formula
C25H27D5N2O4
Formula Weight
429.6
Purity
≥99% deuterated forms (d1-d5)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: solubleMethanol: soluble
SMILES
C[C@]1(C2=CC(O)=CC=C2)[C@H](CN(CC1)CC(C(NCC(O)=O)=O)CC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])C
InChi Code
InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20?,25+/m0/s1/i3D,4D,5D,7D,8D
InChi Key
UPNUIXSCZBYVBB-VZVPYXQSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $666

    Add
    Product Description

    Alvimopan-d5 is intended for use as an internal standard for the quantification of alvimopan (Item No. 23902) by GC- or LC-MS. Alvimopan is a μ-opioid receptor antagonist (Ki = 0.47 nM).1 It is selective over the κ- and δ-opioid receptors (Kis= 100 nM and 12 nM, respectively). Alvimopan inhibits μ-opioid receptor-mediated GTP binding to CHO cell membranes with an IC50 value of 1.7 nM. It inhibits morphine-induced slowing of colorectal transit in mice with an ED50 value of 0.41 mg/kg.2 Alvimopan (0.3 and 1 mg/kg, p.o.) reduces inhibition of gastrointestinal (GI) transit induced by morphine, but not apraclonidine (Item No. 23904), in rats. Formulations containing alvimopan have been used in the treatment of opioid-induced bowel dysfunction.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Le Bourdonnec, B., Barker, W.M., Belanger, S., et al. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg. Med. Chem. Lett. 18(6), 2006-2012 (2008).

    2. Greenwood-Van Meerveld, B., Gardner, C.J., Little, P.J., et al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol. Motil. 16(Suppl. 2), 46-53 (2004).